Journal article

Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies

Dominique Rosillon, Laurence Baril, Maria Rowena Del Rosario-Raymundo, Cosette Marie Wheeler, Susan Rachel Skinner, Suzanne Marie Garland, Jorge Salmeron, Eduardo Lazcano-Ponce, Carlos Santiago Vallejos, Tanya Stoney, Bram ter Harmsel, Timothy Yong Kuei Lim, Swee Chong Quek, Galina Minkina, Shelly Ann McNeill, Celine Bouchard, Kah Leng Fong, Deborah Money, Arunachalam Ilancheran, Alevtina Savicheva Show all

CANCER MEDICINE | WILEY | Published : 2019


BACKGROUND: Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm. METHODS: Serum anti-HPV-16/18 antibodies were determined at baseline and every 12 months in baseline DNA-negative women (N = 2687 for HPV-16 and 2705 for HPV-18) by enzyme-linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polyme..

View full abstract